{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:56:01Z","timestamp":1787496961132,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002923","name":"National Scientific and Technical Research Council","doi-asserted-by":"publisher","award":["PIP 2021-1779"],"award-info":[{"award-number":["PIP 2021-1779"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006668","name":"Fund for Scientific and Technological Research","doi-asserted-by":"publisher","award":["PICT 2016-2714"],"award-info":[{"award-number":["PICT 2016-2714"]}],"id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.leukres.2025.107644","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T12:06:21Z","timestamp":1736251581000},"page":"107644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia"],"prefix":"10.1016","volume":"149","author":[{"given":"Mar\u00eda Bel\u00e9n","family":"Fontecha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"del Rosario Anad\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s Mar\u00eda Mart\u00ednez","family":"Lahitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Weich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Bengi\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Moiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela Freya","family":"Fundia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.107644_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182901","article-title":"Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"12","author":"Lavrov","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2025.107644_bib2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/ijms21041177","article-title":"DNA damage and DNA damage response in chronic myeloid leukemia","volume":"21","author":"Popp","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2025.107644_bib3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107644_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2025.107644_bib5","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3389\/fonc.2020.01348","article-title":"Association of the trough, peak\/trough ratio of imatinib, pyridine-N-oxide imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G with imatinib response in Egyptian chronic myeloid leukemia patients","volume":"10","author":"Omran","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2025.107644_bib6","doi-asserted-by":"crossref","first-page":"2196866","DOI":"10.1080\/16078454.2023.2196866","article-title":"Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies","volume":"28","author":"Younes","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2025.107644_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/OTT.S289306","article-title":"Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia","volume":"15","author":"De Santis","year":"2022","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.leukres.2025.107644_bib8","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7335","article-title":"Beyond BCR::ABL1-the role of genomic analyses in the management of CML","volume":"22","author":"Branford","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.leukres.2025.107644_bib9","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2025.107644_bib10","article-title":"Polymorphisms in the CYP2A6 and ABCC4 genes are associated with a protective effect on chronic myeloid leukemia in the Brazilian Amazon population","volume":"9","author":"Monte","year":"2021","journal-title":"Mol. Genet. Genom. Med."},{"key":"10.1016\/j.leukres.2025.107644_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/pgs-2017-0193","article-title":"Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update","volume":"19","author":"Ankathil","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.leukres.2025.107644_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40199-019-00321-z","article-title":"Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician\u2019s perspective","volume":"28","author":"Pushpam","year":"2020","journal-title":"Daru"},{"key":"10.1016\/j.leukres.2025.107644_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.696960","article-title":"Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukemia","volume":"12","author":"Kaehler","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.leukres.2025.107644_bib14","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.3390\/jcm11206217","article-title":"Association between germline single-nucleotide variants in ADME genes and major molecular response to Imatinib in chronic myeloid leukemia patients","volume":"11","author":"Estrada","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.leukres.2025.107644_bib15","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.3390\/ijms24043303","article-title":"Impact of ABCG2 and ABCB1 polymorphisms on imatinib plasmatic exposure: an original work and meta-analysis","volume":"24","author":"Dalle Fratte","year":"2023","journal-title":"Int. J. Mol. Sci"},{"key":"10.1016\/j.leukres.2025.107644_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3892\/or.2022.8296","article-title":"p53 reactivating small molecule PRIMA\u20111MET\/APR\u2011246 regulates genomic instability in MDA\u2011MB\u2011231 cells","volume":"47","author":"Amirtharaj","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.leukres.2025.107644_bib17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.21037\/tcr.2016.11.75","article-title":"Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis","volume":"5","author":"Carr","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.leukres.2025.107644_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.leukres.2025.107644_bib19","doi-asserted-by":"crossref","first-page":"a026302","DOI":"10.1101\/cshperspect.a026302","article-title":"Genetic modifiers of the p53 pathway","volume":"6","author":"Basu","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.leukres.2025.107644_bib20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jmcb\/mjz052","article-title":"Common genetic variants in the TP53 pathway and their impact on cancer","volume":"11","author":"Barnoud","year":"2019","journal-title":"J. Mol. Cell Biol"},{"key":"10.1016\/j.leukres.2025.107644_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1093","article-title":"The codon 72 polymorphic variants of p53 have markedly different apoptotic potential","volume":"33","author":"Dumont","year":"2003","journal-title":"Nat. Genet"},{"key":"10.1016\/j.leukres.2025.107644_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ijc.11548","article-title":"p53 polymorphic variants at codon 72 exert different effects on cell cycle progression","volume":"108","author":"Pim","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2025.107644_bib23","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1038\/sj.onc.1209405","article-title":"Trp53-dependent DNA-repair is affected by the codon 72 polymorphism","volume":"25","author":"Siddique","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2025.107644_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","article-title":"A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans","volume":"119","author":"Bond","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2025.107644_bib25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/sj.onc.1210199","article-title":"A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans","volume":"26","author":"Bond","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2025.107644_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ccr.2010.12.019","article-title":"The MDM2 promoter SNP285C\/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians","volume":"19","author":"Knappskog","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2025.107644_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ijc.29358","article-title":"Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon","volume":"137","author":"Gansmo","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2025.107644_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1479-7364-6-15","article-title":"Identification of functional DNA variants in the constitutive promoter region of MDM2","volume":"6","author":"Lalonde","year":"2012","journal-title":"Hum. Genom"},{"key":"10.1016\/j.leukres.2025.107644_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcmd.2016.05.007","article-title":"TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome","volume":"59","author":"Weich","year":"2016","journal-title":"Blood Cells Mol. Dis"},{"key":"10.1016\/j.leukres.2025.107644_bib30","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","article-title":"Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase","volume":"140","author":"Lauseker","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107644_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.gene.2012.01.004","article-title":"A 40-bp insertion\/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population","volume":"497","author":"Dong","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.leukres.2025.107644_bib32","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00216-008-2416-y","article-title":"Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis","volume":"394","author":"Chen","year":"2009","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.leukres.2025.107644_bib33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/mc.22061","article-title":"MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving Imatinib","volume":"53","author":"Liu","year":"2014","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.leukres.2025.107644_bib34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.18632\/oncotarget.123","article-title":"Prognostic impact of the MDM2 SNP309 allele in leukemia and lymphoma","volume":"1","author":"Post","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2025.107644_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.12659\/MSM.892919","article-title":"Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia","volume":"21","author":"Ou","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.leukres.2025.107644_bib36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000369522","article-title":"Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis","volume":"133","author":"He","year":"2015","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2025.107644_bib37","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.3109\/10428194.2012.691485","article-title":"MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects","volume":"53","author":"Zhuo","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2025.107644_bib38","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.7754\/Clin.Lab.2017.170413","article-title":"The relationship between MDM2 T309G polymorphism and leukemia in the chinese population: evidence from a meta-analysis","volume":"63","author":"Zhao","year":"2017","journal-title":"Clin. Lab."},{"key":"10.1016\/j.leukres.2025.107644_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233808","article-title":"Fine-scale genomic analyses of admixed individuals reveal unrecognized genetic ancestry components in Argentina","volume":"15","author":"Luisi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2025.107644_bib40","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1055-9965.EPI-07-0634","article-title":"MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies","volume":"16","author":"Hu","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:37:27Z","timestamp":1778668647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"alternative-id":["S0145212625000049"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107644","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107644"}}